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The nuclear receptor retinoid acid receptor-related orphan
receptor t (RORt) is a master regulator of the Th17/IL-17
pathway that plays crucial roles in the pathogenesis of autoim-
munity. RORt has recently emerged as a highly promising tar-
get for treatment of a number of autoimmune diseases. Through
high-throughput screening, we previously identified several
classes of inverse agonists for RORt. Here, we report the crystal
structures for the ligand-binding domain of RORt in both apo
and ligand-bound states. We show that apo RORt adopts an
active conformation capable of recruiting coactivator peptides
and present a detailed analysis of the structural determinants
that stabilize helix 12 (H12) of RORt in the active state in the
absence of a ligand. The structures of ligand-bound RORt
reveal that binding of the inverse agonists disrupts critical inter-
actions that stabilize H12. This destabilizing effect is supported
by ab initio calculations and experimentally by a normalized
crystallographic B-factor analysis. Of note, the H12 destabiliza-
tion in the active state shifts the conformational equilibrium of
RORt toward an inactive state, which underlies the molecular
mechanism of action for the inverse agonists reported here. Our
findings highlight that nuclear receptor structure and function
are dictated by a dynamic conformational equilibrium and that
subtle changes in ligand structures can shift this equilibrium in
opposite directions, leading to a functional switch from agonists
to inverse agonists.
The Th17 lineage of T helper cells plays an essential role in
protective immunity against a variety of bacteria such as Myco-
bacteria tuberculosis and Staphylococcus aureus and patho-
genic fungi such as Candida albicans (1). Individuals with
genetic defects in the Th17 pathway are susceptible to recur-
rent bacterial infections and often develop unrelenting chronic
mucocutaneous candidiasis (2, 3). However, Th17 cells, which
produce the eponymous IL-17A (often simply referred to as
IL-17) and other proinflammatory cytokines, including IL-17F,
IL-21, IL-22, and granulocyte-macrophage colony-stimulating
factor (GM-CSF), are also potent inducers of multiple autoim-
mune diseases in animal models (4 – 8) and are strongly impli-
cated by human genetic studies in the pathogenesis of most
common human autoimmune diseases, including psoriasis,
psoriatic arthritis, Crohn’s disease, ankylosing spondylitis,
rheumatoid arthritis, and multiple sclerosis (9 –13). Given the
prominent roles of the Th17/IL-17 pathway in autoimmunity,
therapeutic interventions targeting this pathway have been
intensely pursued. Two monoclonal antibodies (mAb) target-
ing IL-17A, secukinumab (Cosentyx) and ixekizumab (Taltz),
have been approved recently for the treatment of moderate to
severe plaque psoriasis. Secukinumab is also approved for pso-
riatic arthritis and ankylosing spondylitis (14). In phase 3 clin-
ical trials, both secukinumab and ixekizumab have demon-
strated remarkable efficacy for treatment of psoriasis with
90% of patients achieving a 75% reduction in psoriasis area
and severity index (PASI75) and 40% achieving a PASI100
response with complete clearing of skin lesions (15). Similar
efficacy has been achieved by brodalumab (Siliq), a mAb target-
ing the IL-17 receptor IL-17RA, which was recently approved
by the United States Food and Drug Administration to treat
adults with moderate to severe plaque psoriasis (16). Other
mAbs, such as guselkumab, tildrakizumab, risankizumab (BI
655066), and AMG 139, that target the p19 subunit of IL-23, a
critical cytokine for pathogenic Th17 lineage commitment and
expansion, also show excellent efficacy for psoriasis (15). Collec-
tively, the success of these biologics has strongly validated clini-
cally IL-17, IL-17R, and IL-23, all key players in the Th17 pathway,
as valuable therapeutic targets for autoimmune diseases.
The nuclear receptor (NR)2 retinoid acid receptor-related
orphan receptor t (RORt) is a master transcription factor of
Th17 cells, being both necessary and sufficient for IL-17 expres-
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sion, and it is essential in promoting Th17 cell differentiation
while suppressing the Th1 program (17, 18). RORt is also
required for the production of IL-17 from other cell types,
including  T cells, invariant natural killer T cells, and group 3
innate lymphoid cells, and is necessary for Th17 cells to pro-
duce other proinflammatory cytokines such as IL-22, GM-CSF,
and the IL-23R (19). Therefore, small-molecule modulators
against RORt are also a highly attractive therapeutic modality
that has the potential for meaningful pharmacological differen-
tiation from the specific anti-IL-17 or anti-IL-23 mAbs. Many
small-molecule modulators of RORt have been reported in the
literature in recent years, and two compounds have reached
phase 2 clinical trials for treatment of psoriasis (20 –22).
There are three members in the ROR subfamily of human
NRs as follows: ROR (RORA, NR1F1), ROR (RORB, NR1F2),
and ROR (RORC, NR1F3). The members of the subfamily
share about 50% sequence identity in their ligand-binding
domains (LBD). Two isoforms of ROR exist: the canonical
ROR (ROR1) and RORt (ROR2), which lacks the first 21
N-terminal amino acids due to alternative promoter usage. The
ROR isoform is expressed in most tissues and is involved in
many physiological functions (23). In contrast, RORt is solely
expressed in lymphoid lineage cells of the immune system, con-
sistent with its essential role in the development of lymph nodes
as well as Th17 cells (23). Despite the word “orphan” in ROR’s
name, recent studies with sterol auxotroph cells have convincingly
shown that sterol lipids, including certain cholesterol biosynthetic
intermediates and oxysterols, are physiological ligands for ROR
(24–26). An important link between lipid metabolism and regula-
tion of Th17 pathogenicity was established recently by the discov-
ery that CD5 antigen-like (CD5L) acts as a negative regulator that
alters the balance of lipid saturation and directly affects the avail-
ability of sterol ligands for RORt (27).
Crystal structures of ROR LBD in complex with hydroxy-
cholesterols and various synthetic ligands have been reported
(28 –36). But to our knowledge, no apo structure of ROR LBD
has yet been published. Here, we report the crystal structures of
RORt LBD in both apo and ligand-bound states with two novel
classes of synthetic ligands. The apo RORt structure adopts a
predominantly active conformation, which is supported by the
NMR experiments in solution. Density functional theory (DFT)
calculations were used to elucidate the energetics of the structural
determinants underlying the active conformation of RORt. A
common theme for the structural mechanism of action of the two
distinct classes of inverse agonists was revealed from analyses
of the respective complex structures and normalized crystallo-
graphic B-factors. We emphasize that the dynamic conforma-
tional equilibrium is a fundamental attribute to understand NR
structure and function. Indeed, subtle changes in ligand structures
can shift the equilibrium in opposite directions and lead to a func-
tional switch from an agonist to an inverse agonist.
Results
Production and crystallization of SRC2 peptide-tethered
RORt-LBD
Structural studies of NRs are often carried out in the pres-
ence of carefully chosen cofactor peptides that bind and stabi-
lize the receptors, as is the case in the first crystallographic
study of the RORt-LBD (28). When examining the published
crystal structure (PDB code 3L0L), we noticed that the C–C
distance is only 8 Å between the first resolved N-terminal resi-
due of the steroid receptor coactivator-2 (SRC2) peptide and
the C-terminal residue (Ser-507) of the RORt-LBD. Modeling
suggested that it might be possible to covalently tether an SRC2
peptide to the C terminus of RORt-LBD via a simple -GGG-
linker. The tri-glycine linker provides the maximal conforma-
tional flexibility to preserve the native interactions between the
tethered partners with minimal interference. The tethered sys-
tem is thermodynamically more stable than the untethered
complex due to the reduction of macroscopic translational
entropy through tethering (37, 38). We therefore produced the
His6-RORt-LBD(260 –507) -GGG- EKHKILHRLLQDS (SRC2
peptide) construct and expressed it in Escherichia coli. The chi-
meric protein expressed well in a soluble form and was straight-
forward to purify using standard affinity and size-exclusion
chromatography (see under “Experimental procedures”). Sim-
ilar approaches have been used in the study of the PXR-LBD–
SRC-1p complex (39), as well as MHC-II–peptide complexes
and other protein–protein interactions (40, 41). Without the
complication of achieving the right stoichiometry for the pep-
tide/receptor mixture, the apo crystals of RORt-LBD with
tethered SRC2 peptide could be reproducibly obtained by sit-
ting or hanging drop vapor diffusion at room temperature (see
under “Experimental procedures”). In most cases, co-structures
with ligands were obtained by soaking of compounds into
the apo RORt-LBD crystals. Very occasionally, co-crystal-
lization, where a compound was pre-incubated with the pro-
tein solution prior to crystallization, was also used to solve a
co-complex structure. This is the case for compound 2
(Table 2), for which co-structures were obtained through
both soaking and co-crystallization.
Apo RORt-LBD structure and the structural determinants for
its active conformation
The apo RORt-LBD structure was solved in the space group
P41212 with one polypeptide chain per asymmetric unit. The
statistics for data collection and refinement are summarized in
Table 1. The apo RORt-LBD structure is very similar to that of
the 25-hydroxycholesterol (25-HC)-bound RORt (28) (PDB
code 3L0L), with r.m.s.d. of backbone and all heavy atoms at
0.54 and 1.20 Å between the two structures, respectively (Fig.
1). Similar to 25-HC-bound RORt, the apo structure assumes
an active conformation, with H12 as an integral part of the AF-2
surface that captures the SRC2 coactivator peptide (Fig. 1A).
The -GGG- linker residues are in a flexible loop conformation
with weak electron densities and elevated B-factor values.
There are no specific interactions between the glycine linker
and the rest of the protein. Notably, the apo RORt contains a
large ligand-binding pocket, with a cavity volume of 940 Å3 (Fig.
1A). As is typical for nuclear receptors, the ligand-binding
pocket is predominantly hydrophobic (575 Å3, 61% of total cav-
ity volume). In contrast, the cavity volumes for hydrophilic,
basic, and acidic compositions are 161 Å3 (17%), 178 Å3 (19%),
and 26 Å3 (3%), respectively. Interestingly, almost the entire
25-HC can fit comfortably in the ligand-binding pocket of apo
Apo and ligand-bound RORt structures
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RORt; only some adaptive side-chain movements from His-
323, Leu-324, and Mer-365 are required to accommodate the
B-ring of 25-HC (Fig. 1B). In fact, the His-323 side-chain con-
formation switch constitutes the largest structural difference
between the apo and 25-HC bound RORt. It has been shown
recently that a number of cholesterol precursors, such as lanos-
terol and desmosterol as well as oxysterols, are the natural
endogenous ligands for RORt (24 –26). Our structure of apo
RORt suggests that the ligand-binding pocket may be pre-
formed to readily accommodate such ligands.
The question then arises as to how RORt keeps H12 in the
active conformation and maintains a large cavity in its interior
in the absence of a ligand. One key structural element is the
His-479 –Tyr-502–Phe-506 triplet. Tyr-502 and Phe-506
reside on the same face of the two-turn H12, forming close
interactions with His-479 on H11 (Fig. 1C). The most promi-
nent of the interactions is the H-bond between the phenol of
Tyr-502 and the imidazole N2 of His-479. Here, the N2 of
His-479 acts most likely as an H-bond acceptor, and thus His-
479 is in the neutral (uncharged) form. His-479 also engages in
an edge-to-face aromatic packing interaction with Phe-506.
Furthermore, a favorable aromatic ring packing exists between
Tyr-502 and Phe-506. The side-chain rotamer of His-479 is
further stabilized through a water-mediated H-bond network
linking its N1 to the backbone carbonyl oxygen of Gln-475. To
more quantitatively assess the significance of these interac-
tions, an ab initio calculation of the interaction energy among
the side chains of the HYF triplet was carried out using the DFT
method (see under “Experimental procedures”). The DFT cal-
culation used the Truhlar hybrid meta exchange-correlation
functional M06-2X with a 6 –32G** basis set, which is well-
suited for calculating non-covalent interactions such as
H-bonding and -stacking that are dominated by dispersion
forces (42, 43). The resulting interaction energy for the HYF
triplet is 12.90 kcal/mol. This is a very significant energy that
provides the anchoring force to stabilize H12 of RORt in the
active conformation in the absence of a ligand. The HYF triplet
is conserved among the // isoforms of the ROR subfamily
but is not found in any other NRs. For example, the correspond-
ing residues in PPAR are His-449 –Leu-469 –Tyr-473 with no
H-bonding among them. The interaction energy is only 3.00
kcal/mol when PPAR is in the active conformation and is neg-
ligible when PPAR is in the inactive conformation (interaction
energies calculated using the same DFT method, with PPAR
coordinates from PDB code 1PRG) (see supplemental Fig. S1).
Because of the lack of a stabilizing triplet in PPAR, H12 and
indeed the entire ligand-binding pocket of apo PPAR exhibit
significant conformational mobility as revealed by NMR (44)
and fluorescence anisotropy studies (45). The crystal structure
of apo PPAR also showed elevated crystallographic B-factor
values for the H12 and ligand-binding pocket residues, and H12
was in fact captured in both active and inactive states (46).
There is another unique structural element in ROR, namely
the H11 helix. Again, H11 is present in all three isoforms of
the ROR subfamily but is not found in most of the other NRs. As
illustrated in Fig. 1D, H11 and H12 together bury 322 Å2 of
solvent-accessible surface area, which is 29% of H12’s total sur-
face area. Therefore, a notable helical packing interaction exists
between H11 and H12. Helical packing in general is an impor-
tant stabilizing force in protein folding and in protein-protein
interactions (47, 48). Here, the H11–H12 packing contributes
to stabilize H12 in the active conformation. Interestingly, H12
and the SRC2 peptide together bury 509 Å2 of solvent-accessi-
ble surface area (Fig. 1D), which amounts to 46% and 32% of
Table 1
Data collection and structure refinement statistics
Values in parentheses are for the last resolution shell. r.m.s.d. is root mean square deviation.
RORt LBD Apo With compound 1 With compound 2 With compound 3
Data collection
Wavelength (Å) 1.00 1.00 1.00 1.00
Space group P41212 P41212 P41212 P41212
Unit cell dimensions (a, b, c) (Å) 61.27, 61.27, 154.23 62.31, 62.31, 154.18 60.47, 60.47, 155.00 62.96, 62.96, 155.32
(, , ) (°) 90.00, 90.00, 90.00 90.00, 90.00, 90.00 90.00, 90.00, 90.00 90.00, 90.00, 90.00
Mosaicity 0.31 0.19 0.58 0.48
Resolution range (Å) 43.33–1.95 (2.02–1.95) 77.09–2.04 (2.05–2.04) 155.00–2.23 (2.233–2.226) 77.66–2.34 (2.342–2.335)
Total no. of reflections 258,813 261,150 182,584 175,314
No. of unique reflections 21,942 20,213 14,904 14,031
Average redundancy 11.80 (12.56) 12.9 (12.6) 12.3 (11.9) 12.5 (13.3)
Completeness (%) 98.5 (98.0) 100.0 (100.0) 100.0 (100.0) 100.0 (100.0)
Rmerge 0.074 (0.593) 0.086 (1.202) 0.099 (1.490) 0.114 (1.903)
Rmeas 0.078 (0.618) 0.090 (1.254) 0.104 (1.558) 0.119 (1.978)
Output I/I 14.4 (3.2) 25.0 (2.2) 15.4 (2.4) 18.9 (2.4)
Refinement
Resolution range (Å) 43.33–1.95 39.65–2.04 39.28–2.23 38.62–2.34
Reflections, work/test (%) 21,934/1123 (5.12%) 20,131/1002 (4.98%) 14,824/739 (4.99%) 13,954/704 (5.05%)
Completeness for range (%) 98.82 99.95 99.85 99.89
No. of atoms 2300 2346 2268 2215
No. of waters 159 190 102 80
Rwork 0.1957 0.1866 0.1932 0.1836
Rfree 0.2298 0.2075 0.2344 0.2161
r.m.s.d. bond lengths (Å) 0.004 0.003 0.002 0.005
r.m.s.d. bond angles (°) 0.731 0.621 0.534 0.600
Average B value (Å2) 36.62 33.79 45.54 42.07
Ramachandran plot
Favored (%) 98.85 97.72 98.85 98.45
Allowed (%) 1.15 2.28 1.15 1.55
Outliers (%) 0.0 0.00 0.00 0.00
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total surface area for H12 and the SRC2 peptide, respectively,
and it underscores the critical role H12 plays in recruiting
coactivators. In summary, RORt utilizes a unique HYF triplet
to provide significant interaction energy to anchor H12 in the
active conformation, which is further stabilized by helical pack-
ing with a unique H11 element.
RORt-LBD is capable of recruiting coactivator peptide in the
absence of a ligand
A hallmark of NR in the active state is its ability to recruit
coactivators to initiate transcription. To investigate whether
apo RORt is competent to bind coactivators, we carried out
solution NMR studies using 13C/15N-labeled samples from a
RORt(259 –518) construct as well as the crystallography con-
struct RORt(260 –507)-G3-SRC2. The RORt(259 –518) con-
struct encompasses the entire RORt ligand-binding domain,
without C-terminal truncation beyond H12 and without teth-
ering of a coactivator peptide. As shown in Fig. 2, titration of the
SRC2 peptide into the 13C/15N-labeled RORt(259 –518) pro-
tein resulted in distinctive chemical shift perturbations to the
backbone amide peaks in the 15N-TROSY spectra (Fig. 2A) as
well as to the methyl peaks in the 13C-HSQC spectra (Fig. 2B) of
RORt(259 –518). These results clearly demonstrate that the
native RORt-LBD in solution is capable of binding to a coacti-
vator peptide, such as the SRC2 peptide used here, in the
absence of a ligand. Furthermore, the backbone 15N-TROSY
spectrum of the SRC2-bound RORt(259 –518) bears strong
resemblance to that of the RORt(260 –507)-G3-SRC2 (Fig.
2C). Some of the differences between the two spectra with pro-
ton chemical shifts centered around 8 ppm in Fig. 2C are likely
due to the difference of C-terminal sequences after residue 507.
The resemblance is even more striking for the methyl reso-
nances in the 13C-HSQC spectra (Fig. 2D and compare with B),
with the perturbed methyl peaks from RORt(259 –518) shift-
ing to the exact positions of the corresponding methyl peaks
from RORt(260 –507)-G3-SRC2. Therefore, the SRC2-teth-
ered RORt-LBD largely recapitulates the native RORt-LBD
in the presence of the SRC2 peptide in solution. It should be
noted from qualitative assessments of the NMR spectra that the
native apo RORt-LBD exhibits more conformational flexibil-
Figure 1. Apo structure of RORt LBD and structural determinants for its active conformation. A, schematic representation of the apo RORt LBD is
shown in pale green, with H11, H12, and SRC2 peptide segments highlighted in green, dark red, and xenon blue, respectively. The large cavity present in the apo
RORt is shown in dark gray. His-323, His-479, Tyr-502, and Phe-506 are highlighted as sticks. B, superposition of the apo RORt structure in dark red with the
RORt LBD bound with 25-HC in light gray (PDB code 3L0L); 25-HC is drawn as green sticks. Close-up views are shown for the SRC2 peptide and H12 regions and
for the apo state cavity with 25-HC and His-323, His-479, Tyr-502, and Phe-506 highlighted. The B-ring of 25-HC protrudes out of the apo cavity and would clash
with the side chain of His-323 in the apo state. C, close interactions among the His-479 –Tyr-502–Phe-506 triplet in RORt help to anchor helix 12 in the active
conformation. Color scheme follows that of A. The H-bond between His-479 and Tyr-502 is indicated as black dashes. D, helical packing between H11, H12 and
the SRC2 peptide provides further stabilization. The solvent-accessible surface areas of the three helical elements are depicted as meshes and highlighted in a
close-up view. Color scheme follows that of A.
Apo and ligand-bound RORt structures
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ity in solution than the SRC2-tethered apo RORt-LBD. There
is also evidence that the C-terminal residues beyond H12 (i.e.
residues 508 –518) in the native RORt-LBD are largely disor-
dered both in solution and in crystal forms.3
Binding mode of two diverse classes of RORt inverse agonists
and the structural mechanism of action (sMOA)
Two classes of RORt inverse agonists were discovered
through a high-throughput screening campaign using a RORt
gene reporter assay (see under “Experimental procedures”).
Two representative compounds from the two classes are shown
in Table 2. These compounds had sub-micromolar binding
affinity to RORt in a fluorescence polarization (FP) competi-
tion assay using a probe with similar potency in a cell-based RORt reporter gene assay. More importantly, these com-
pounds also demonstrated Th17 primary cell activity, inhibit-
ing the production of IL-17.
A 2.04-Å resolution co-complex structure of compound 1
with RORt-LBD was obtained through soaking of the com-
3 Unpublished in-house NMR and X-ray data suggest that the C-terminal res-
idues beyond H12 (i.e. residues 508 –518) in the native RORt-LBD are
largely disordered both in solution and in crystal forms.
Figure 2. NMR spectra of RORt(259 –518) and RORt(260 –507)-G3-SRC2. A and B, overlays of backbone
15N-TROSY (A) and methyl-13C-HSQC (B) spectra
of RORt(259 –518) in apo (black) and in SRC2 peptide-bound state (red). Some perturbed peaks are highlighted with green arrows. C and D, overlays of
backbone 15N-TROSY (C) and methyl-13C-HSQC (D) spectra of RORt(260 –507)-G3-SRC2 (blue) and SRC2 peptide-bound RORt(259 –518) (red). The methyl
peaks highlighted in Fig. 3B are indicated with the same green arrows in Fig. 3D.
Table 2
Inverse agonists of RORt reported in this study
Apo and ligand-bound RORt structures
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pound in the apo RORt crystals. As shown in Fig. 3A, com-
pound 1 binds across the entire cavity of the ligand-binding
pocket, starting from one end with the pyridine nitrogen mak-
ing a strong H-bond with Arg-367, the urea carbonyl in the
middle forming a water-mediated H-bond with the backbone
carbonyl of Phe-377, and the isobutylene moiety extending into
a highly hydrophobic region lined with aliphatic and aromatic res-
idues, and ending with the phenyl amide interacting with the crit-
ical HYF triplet. Most notably, the phenyl ring of compound 1
protrudes into the His-479–Tyr-502 pair, disrupting the H-bond
Figure 3. Binding modes of compounds 1–3. Compounds are shown in magenta in the ligand-binding pocket of RORt of the respective co-complex
structures. The overall structures of ligand-bound RORt LBD are depicted as schematics, with H11, H12, and SRC2 peptide colored as in Fig. 1A and key
ligand-binding site residues highlighted as sticks. The simulated annealing omit difference maps were calculated with the entire compound molecules omitted
and plotted in blue at 2.5  level for compounds 1 and 2 and at 3.0  level for compound 3. The apo structure of RORt is shown in pale green as in Fig. 1A.
Compounds are shown as magenta sticks. H-bonds are indicated as black dashes. A, overall binding mode of compound 1. B, close-up view of disruption of
compound 1 to the His-479 –Tyr-502–Phe-506 triplet in RORt. C, overall binding mode of compound 2. D, close-up view of disruption of compound 2 to the
His-479 –Tyr-502–Phe-506 triplet in RORt. E, overall binding mode of compound 3. F, cluster of aryl interactions are formed between compound 3, the
His-479 –Tyr-502–Phe-506 triplet, and Trp-317, which further stabilize RORt in the active conformation. Compound 1 and His-479 from compound 1-bound
RORt are shown in yellow for comparison; only protein atoms were used in the superposition.
Apo and ligand-bound RORt structures
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between them. His-479 is forced to adopt a different side-chain
conformation, which is stabilized through the formation of two
new H-bonds with the amide linker of compound 1 and the back-
bone carbonyl of Leu-475, respectively (Fig. 3B). The two aromatic
residues on H12, Tyr-502 and Phe-506, however, lose their close
interactions with His-479. In this case, the interaction energy of
the HYF triplet is reduced to only 1.4 kcal/mol as calculated
using the same DFT protocol, which amounts to a loss of 11.5
kcal/mol stabilizing energy for H12 compared with the apo struc-
ture. Therefore, the disruption by compound 1 of the critical
H-bond between His-479 and Tyr-502, with a concurrent loss of
the aromatic packing between His-479 and Phe-506, results in the
severe destabilization of H12 in its active conformation.
Compound 2 is structurally very different from compound 1.
To understand how compound 2 binds to RORt and what is
the structural basis for its mechanism of action, we also solved
its co-complex structure with RORt-LBD. Both soaking and
co-crystallization approaches were attempted, and both yielded
co-structures that were highly similar to each other; therefore,
only the structure from co-crystallization is reported here. Despite
having completely unrelated chemical structures, compounds 1
and 2 occupy essentially the same space in the ligand-binding
pocket of RORt (Fig. 3C). The isobutyl group of compound 2
aligns with the pyridyl ring of compound 1, although the former
does not engage Arg-367 in an H-bond. The methyl piperidine
moiety of compound 2 fills the same hydrophobic sub-pocket that
accepts the isobutylene moiety of compound 1. A very similar
water-mediated H-bond is observed between compound 2 and the
backbone carbonyl of Phe-377. Most interestingly, the chloroben-
zyl group of compound 2 also intercalates into the His-479–Tyr-
502 pair, forcing a side-chain conformation switch for His-479 and
breaking up the His-479–Tyr-502 H-bond (Fig. 3D). The interac-
tion energy of the HYF triplet is lost almost completely at 1.1
kcal/mol based on the DFT calculation. The loss of favorable inter-
actions for His-479 is partly compensated for by the formation of
new H-bonds with the amide linker of compound 2 and the back-
bone carbonyl of Leu-475, in a way reminiscent of the case with
compound 1. Therefore, it appears that we have uncovered a com-
mon mechanism by which diverse chemical scaffolds may exert
inverse agonist activities against RORt through direct disruption
of the tightly interacting HYF triplet thereby destabilizing the
active conformation of RORt.
Differential B-factor analysis
The crystallographic B-factor, also called atomic displace-
ment parameter, is a measure of atomic displacement from its
equilibrium or mean position, and it captures structural flexi-
bility as well as positional variations due to thermal vibrations.
Not surprisingly, B-factors have been widely exploited to probe
protein flexibility (49), thermal stability (50), enzyme-active
sites (51), and more recently to provide an integrated descrip-
tion of protein dynamics by combining with order parameters
derived from solution NMR studies (52). Likewise, we reasoned
that the destabilization of RORt’s H12 due to the binding of
compounds 1 and 2 should be manifested by elevated B-factors
in the H12 region of the respective complex structures. Typi-
cally, B-factor analyses of proteins are performed to compare
different regions of the same protein structure. Here, we want
to compare B-factors in the same regions of the protein from
two different structures. To allow for a meaningful comparison
of B-factors between the H12 region of interest in the bound
state and the corresponding apo state, we first introduce a mod-






where B is the median B-factor, calculated separately for
backbone and side-chain atoms, respectively. B can be viewed
as a normalized B-factor. It is not influenced by variation of
overall B-factors between different crystals. B is dimensionless.
A negative (positive) B value can be interpreted as indicative of
higher (lower) rigidity and stability than the average of the
structure. To identify regions of altered flexibility or stability in
the compound-bound complex versus the corresponding apo





An atom with positive Bdiff means it has elevated flexibility and
is less stable compared with its apo state. Conversely, an atom with
negative Bdiff means it is further rigidified and more stable than in
Figure 4. Differential B-factor plot. Normalized B-factor differences (see text) are displayed for the structural elements as a blue-white-red color ramp with
blue indicating the most negative value (stabilization) and red the most positive value (destabilization). The compound chemical structure is drawn at the top
of each respective panel. A, H11 and H12 of RORt in complex with compound 1. B, H11 and H12 of RORt in complex with compound 2. C, H11 and H12 of
RORt in complex with compound 3.
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the apo state. In Fig. 4, the Bdiff values are visualized with color
ramps from blue (negative) to white (0) to red (positive) for
H11 and H12 of RORt in complex with compounds 1 (Fig.
4A) and 2 (Fig. 4B), respectively. As already suggested by the
DFT calculations, the destabilization of H12 and the HYF
triplet by the ligands is reflected in the Bdiff plots by red
colorations of H12.
In addition to showing how ligands can destabilize H12, we
surmised that it should also be possible that ligands can further
stabilize H12 in the active conformation. To this end, we stud-
ied compound 3, which was synthesized as an analog of com-
pound 1 following a typical structure-activity relationship
(SAR) optimization strategy. Compound 3 is structurally very
similar to compound 1 except having an ether linker in place of
an amide in compound 1. Compound 3 showed good binding to
RORt (FP Kd  0.19 M), but surprisingly it did not register an
inhibitory activity in the reporter gene assay (IC50 3.3 M). To
understand its unexpected lack of inverse agonist activity, we
solved a 2.34 Å resolution co-complex structure of compound 3
with RORt-LBD through soaking of the compound in the apo
RORt crystals (Fig. 3E). Surprisingly, compound 3 does not
disrupt the tightly interacting HYF triplet. Instead, the phenyl
ether of compound 3 points toward Trp-317 and forms a tightly
packed aromatic cluster with the HYF triplet and Trp-317
together, thereby further stabilizing RORt in the active con-
formation (Fig. 3F). This stabilization effect is confirmed by the
differential B-factor analysis shown in Fig. 4C. Because the
inverse agonist activities of compound 1 and 2 are due to their
destabilization effect on the active receptor conformation of
RORt as discussed above, it is expected that stabilization of the
active conformation by compound 3 would elicit the opposite
effect on the receptor. In other words, compound 3 should be
an agonist of RORt. A fluorescence polarization (FP)-based
coactivator recruitment assay using a fluorescein-labeled
coactivator peptide (D22) containing the LXXLL motif was
developed to test this. As shown in Fig. 5, compound 3 indeed
behaves as an agonist by enhancing the recruitment of D22 with
an EC50 of 0.54 M.
Discussion
Nuclear receptors are ligand-regulated transcription factors
that orchestrate the assembly of coregulatory complexes
(coactivators and corepressors) to modulate transcription
through chromatin-remodeling activities (53). The role of a
high affinity endogenous ligand is “classically” viewed as a trig-
ger of a molecular switch whereby the binding of the ligand
induces a conformational change involving H12 that switches
the receptor from an inactive or repressed state to an active
state competent for recruitment of coactivators and subse-
quent initiation of transcription (54). This conceptually appeal-
ing but overly simplistic view of NR activation is still frequently
cited in the literature, even though mounting evidence has
accumulated revealing NR proteins are highly dynamic and ver-
satile. For instance, REV-ERB (NR1D1) and REV-ERB
(NR1D2) do not even have a H12 and use heme as a ligand (55,
56); NR activities are spatially and temporally regulated (57)
and involve multiple structural elements with specific higher-
order structures at play (58, 59). NRs are also known to be
regulated by ligand-independent mechanisms such as post-
translational modifications (60, 61). For example, RORt has
been shown to be modulated by both acetylation (62) and ubiq-
uitination (63) with direct functional effects on Th17 biology. In
this study, we showed that the apo RORt LBD can adopt an
active conformation with the capability to recruit a coactivator
peptide. We believe that this active conformation is not influ-
enced by the triple-glycine linker because these glycines do not
make any specific contacts with the rest of the protein in the
crystal structure and are highly flexible with very weak electron
densities and high B-factors. In full support of this notion, our
solution NMR studies with the RORt(259 –518) construct
demonstrated that the non-tethered native RORt LBD is capa-
ble of directly binding to the SRC2 coactivator peptide in the
absence of a ligand, and the NMR spectra of SRC2-bound
RORt LBD closely resemble those of the SRC2-tethered
RORt-LBD, suggesting both having similar conformations in
solution.
A number of NRs, such as estrogen-related receptor 
(ESRRG) (NR3B3), nerve growth factor IB (NGFIB) (NR4A1),
nuclear receptor-related 1 (NURR1) (NR4A2), and liver recep-
tor homolog-1 (LRH-1) (NR5A2), are capable of adopting
active conformations independent of ligands (64). The crystal
structure of apo LRH-1 (65) in particular shows an active con-
formation with a voluminous but empty cavity (820 Å) in the
ligand-binding pocket, very similar to the case with apo RORt
revealed here. The specific structural elements stabilizing apo
LRH-1 in the active conformation have been attributed to an
extended H2 that acts as an extra layer with optimal helical
packing against H3 to hold AF2 helices, including H12, in the
activated state (65). In this study, we have carried out detailed
structural and computational analyses to demonstrate that the
tightly interacting His-479 –Tyr-502–Phe-506 triplet is the pri-
mary structural element responsible for anchoring RORt in
the active conformation, which is further strengthened by addi-
tional helical packing with the extra H11 helix. Both the HYF
triplet and the H11 are structural features unique to the ROR
subfamily of NRs.
Figure 5. Agonistic effect of compound 3 as shown in the FP-based
coactivator recruitment assay. The compound concentration is plotted in
logarithmic scale.
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Proteins exist not in a single fixed state but rather as a
dynamic ensemble in the biologically relevant environment.
The apo crystal structure of RORt LBD reported here is only a
snapshot of a continuum of conformations sampled by RORt
in solution. The snapshot revealed by crystallography repre-
sents a low energy state having a dominant population. Under
physiological conditions, RORt should also be able to sample
other lower population (higher energy) states, including inac-
tive ones. In fact, our NMR studies with the RORt(259 –518)
construct have confirmed that RORt can indeed bind directly
to a corepressor peptide derived from the silencing mediator of
retinoid and thyroid hormone receptors-2 (SMRT2) in solution
in the absence of a ligand (supplemental Fig. S2). Therefore, we
have shown that RORt has the conformational elasticity to
bind either a coactivator (active conformation) or a corepressor
(inactive conformation) in solution independent of ligands. It
would be reasonable to posit that in general the presence of
ligands or coregulators can alter the populations of various dis-
tinct states an NR may assume and shift the conformational
equilibrium toward further activation or inactivation of the
receptor. Under this dynamic equilibrium paradigm of NR
modulation, the abundance of specific ligands, coactivators, or
corepressors would dictate the activation state of an NR in a
particular cellular context.
The sMOA revealed by the crystallographic studies of the
two novel classes of RORt inverse agonists dovetails with the
dynamic equilibrium paradigm. Despite their high structural
diversity, the two classes of inverse agonists share a common
sMOA; they both disrupt the critical HYF triplet anchor
thereby destabilizing the active conformation of H12 and shift-
ing RORt toward inactivation. Conversely, an agonist of
RORt should do the opposite. This is the case with compound
3, which forms an extended aromatic cluster together with the
HYF triplet and further stabilizes H12 in the active conforma-
tion. The dynamic picture of H12 mobility and stability in
response to ligand binding is supported by the differential
B-factor analysis as well as the ab initio calculations of the inter-
action energies employed in this study. Recently, cholesterol
biosynthetic intermediates have been identified as natural
ligands for RORt. We believe that these endogenous ligands
work similarly to compound 3 in that they also bind and further
stabilize the active conformation of RORt. Under physiologi-
cal conditions, the actions of endogenous ligands are likely nec-
essary to achieve sustained activation of RORt due to other
factors that can tilt the conformational equilibrium of the
receptor toward repressed states.
Finally, it is interesting to note that subtle changes in the
ligand structure can result in diametrically opposite functional
responses of a nuclear receptor, as demonstrated by the two
structurally very similar urea compounds 1 and 3 reported
here. This phenomenon can be understood most naturally from
examining the dynamic equilibrium of receptor states, as com-
pounds 1 and 3 shift the conformational equilibrium of RORt
in opposite directions. Similar results have been reported by
Rene et al. (35), who showed a class of benzylsulfonamides as
full inverse agonists of RORt with phenylsulfonamide analogs
showing agonistic activities. The underlying sMOA described
by the Genentech group is identical to what we have observed
here, in that the phenylsulfonamides stabilize the active confor-
mation of RORt, and the benzylsulfonamides destabilize it.
The subtleties that minimal variation of ligand structures can
lead to dramatically different functional activities are not lim-
ited to NRs but are in fact well known in the GPCR field (66).
Complex dynamic states are involved in the ligand regulation as
well as signal transduction of GPCRs (67, 68). The dynamic
equilibrium paradigm appears to be a unifying framework
applicable for understanding the subtle structure-activity rela-
tionships often encountered in receptor drug discovery.
Experimental procedures
Cloning, expression, and purification
Constructs for His6-Thr-RORt(260 –507)-GGG-SRC2 and
His6-Thr-RORt(259 –518) were cloned into pET41a(	) vec-
tors. The proteins were expressed in E. coli, strain BL21(DE3).
Cell cultures were grown in TB media under kanamycin control
at 37 °C until the optical absorbance at 600 nm reached 1.0.
Temperature was then reduced to 18 °C, and expression was
induced with 0.5 mM isopropyl 1-thio--D-galactopyranoside.
The 13C/15N-labeled samples were expressed in 13C/15N-en-
riched Bioexpress cell growth media (Cambridge Isotope Lab-
oratories, Inc., catalogue no. CGM-1000-CN). Cells were lysed
in lysis buffer (20 mM Tris, pH 8.0, 150 mM NaCl, 0.5% CHAPS,
2 mM -mercaptoethanol, 10% glycerol, 2 tablets/50 ml prote-
ase inhibitors (Roche Applied Science catalogue no. 12483700),
10 units/ml benzonase nuclease (Sigma catalogue no. E1014),
and 0.1 mg/ml lysozyme). After clarification by centrifugation
at 4 °C, the soluble lysate was loaded onto a His-Trap column
pre-equilibrated with Ni-Eq. buffer (20 mM Tris, pH 8.0, 150
mM NaCl, 2 mM -mercaptoethanol, 10% glycerol, 0.05%
CHAPS), and the protein was eluted out with elution buffer (20
mM Tris, pH 8.0, 150 mM NaCl, 2 mM -mercaptoethanol, 10%
glycerol, 0.05% CHAPS, and 500 mM imidazole). The eluted
protein was further purified by size-exclusion chromatography
on a Superdex 75 column. Finally, the pure RORt protein was
dialyzed into the storage buffer (25 mM HEPES, pH 7.0, 150 mM
NaCl, 2 mM DTT) and concentrated to 9 mg/ml prior to crys-
tallization. For NMR experiments, 13C/15N-labeled protein
samples were purified similarly and exchanged into the final
NMR buffer (see below) and concentrated to 0.22 mM.
Crystallization, data collection, and structure determination
Initial screens of crystallization conditions were carried out
with Crystal Screens I and II from Hampton Research, and NR-
LBD HT-96 screening kit from Molecular Dimensions (MD1–
34), using sitting drop vapor diffusion on a Mosquito instru-
ment at 20 °C. Drops containing 0.1 l of protein mixed with 0.1
l of well solution were equilibrated against 80 l of well solu-
tion. Follow-up optimizations were performed manually using
hanging drop vapor diffusion with drops containing 1 l of
protein mixed with 1 l of well solution equilibrated against 500
l of well solution. Diffraction-quality apo or ligand-bound
RORt crystals were obtained with 2– 8% (w/v) PEG4000, 0.6 M
NaCl, and 0.1 M PIPES, pH 7.0. Crystals were flash-frozen in
liquid nitrogen with cryoprotectant prepared using the corre-
sponding reservoir condition supplemented with 20% glycerol.
Protein–ligand co-crystals were obtained either from soaking
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of the compound into apo RORt crystals or from co-crystalli-
zation of the pre-formed protein–ligand complex solution. For
co-crystallization, a compound was added to the protein stock
solution with a protein–ligand molar ratio of about 1:5. The
complex solution was incubated at room temperature for 40
min and then centrifuged at 14,000 rpm for 35 min prior to
crystallization experiments. For soaking experiments, 3 mM
compound prepared in DMSO stock solution was added in a
drop containing the apo RORt crystals and soaked at room
temperature for 6 h. The soaked crystals were then flash-frozen
in liquid nitrogen using the crystallization solution supple-
mented with 25% PEG400 as a cryoprotectant. X-ray diffraction
data were collected at beamlines X06SA or X06DA (for co-crys-
tals with compound 1) of the Swiss Light Source using Pilatus
6M and 2M-F detectors, respectively. Diffraction data were pro-
cessed using either d*TREK or XDS (69, 70). The initial struc-
ture was determined by molecular replacement with Phaser
(71) as implemented in the PHENIX software suite (72) using
the structure of RORt LBD in complex with 22(R)-hydroxy-
cholesterol (PDB code 3L0J) as a search model. Ligand
geometry restraints were generated using Corina (Molecular
Networks GmbH). Multiple rounds of positional and isotro-
pic B-factor refinement using phenix.refine followed by
manual rebuilding using Coot (73) were carried out for each
structure. The quality of the final model was evaluated using
MolProbity (74). Structural figures were generated using
PyMOL (Schrödinger, LLC).
NMR spectroscopy
All NMR data were acquired at 30 °C on an 800-MHz Bruker
AvanceIII spectrometer equipped with a triple resonance (1H/
13C/15N) cryoprobe. 0.22 mM samples of uniformly 13C/15N-
labeled RORt(259 –518) or RORt(260 –507)-G3-SRC2 in the
same buffer containing 25 mM deuterated HEPES, pH 7.0, 150
mM NaCl, 2 mM DTT, with 10% D2O, 90% H2O were used in the
NMR experiments. Each NMR sample had a volume of 140 l
using 2.5-mm Bruker Match tubes. For the titration experi-
ments, SRC2 peptide was added to the RORt(259 –518) sam-
ple with a final total peptide concentration of 0.4 mM. The 15N-
TROSY and 13C-HSQC experiments were carried out as
described in the literature (75–77).
Fluorescence polarization competitive binding assays
The fluorescence polarization (FP) measurements were con-
ducted using an Envision plate reader (PerkinElmer Life Sci-
ences) using the RORt-SRC2 construct produced in-house
(see above), and a fluorescent TAMRA (Thermo Fisher Scien-
tific, Inc.) probe synthesized with an in-house compound bind-
ing to RORt. Compound was diluted in assay buffer (20 mM
Tris, pH 7.5, 150 mM NaCl, and 0.05% CHAPS), and 10 l of 20
M compound was mixed with 10 l of 2 M RORt-SRC2 in
the same buffer and incubated for 30 min at room temperature.
The TAMRA probe was then added to the mixture at a final
concentration of 15 nM. After 30 min of incubation at room
temperature, the FP signal was measured (excitation wave-
length 531 nm; emission wavelength 595 nm), and the Kd values
were determined as described (78).
RORt-Gal4 reporter gene assay
HEK293T cells were co-transfected with a plasmid pBIND
containing the chimera of the DNA-binding domain of the
yeast Gal4 protein and the ligand-binding domain of human
RORt (Gal4DBD-hRORt LBD), along with the luciferase
reporter plasmid pGL4.31 (luc2P/GAL4UAS/Hygro, Promega).
The positive control was co-transiently transfected with both plas-
mids, and the negative control had only the pGL4.31 promoter
sequence. Assays were assembled in 384-well Greiner plates where
transiently transfected cells and test compound at varying concen-
trations were incubated at 37 °C and 5% CO2 for 20–24 h. The
next day, assay plates were taken out and equilibrated at room
temperature for 20–30 min. Bright-GloTM luciferase assay system
(Promega) was used to detect luciferase production. After addition
of Bright-Glo detection reagent, the plates were incubated at
room temperature for 20 min. The plates were read on an
Envision plate reader to measure luminescence signal. The
relative light unit (RLU) signal was converted to percent of
control value relative to control and blank wells.
IL-17 production in Th17 primary cell assay
Frozen CD4	 T cells (AllCells) were thawed and resus-
pended in X-VIVO media (Lonza) at a cell density of 1 
 106
cells/ml. Skewing cytokines were added to media at the final
concentrations of 30 ng/ml IL-23, 10 ng/ml IL-1, 10 ng/ml
IL-6, 2 ng/ml IL-2, 4 ng/ml TGF1, 5 g/ml IL-4, and 5 g/ml
IFN and mixed with activated beads (Miltenyi Biotec cata-
logue no. 130-091-441) at 1 bead/cell. The cells were incubated
under the stimulatory conditions for 72 h at 37 °C. Skewed cells
were spun and resuspended in Iscove’s media (Invitrogen cata-
logue no. 12440) with a cell density of 1.11 
 106 cells/ml. Cells
were seeded at 90 l/well into Corning black/clear TC-treated
plates (Corning catalogue no. 3603) to give 100,000 cells per
well. 10 l of medium-diluted compounds was added, and
plates were incubated for 2 h at 37 °C and 5% CO2. 50 l of
cytokine/bead mixture was added to all wells except blank
wells, which received media only. Cell plates were incubated at
37 °C and 5% CO2 for 48 h. Afterward, plates were spun, and 50
l of supernatant from each well was collected and transferred
to MSD Vplex IL-17A assay plate (Meso Scale Diagnostics,
LLC) for detection of IL-17 expression, following the manufa-
cturer’s protocol. IC50 values were obtained by fitting 10-point
concentration-response data to a four-parameter logistic equa-
tion in ActivityBase (ID Business Solutions Ltd.).
Coactivator recruitment assay
An FP-based assay was developed for coactivator recruit-
ment. The fluorescence polarization measurements were con-
ducted on an Envision (PerkinElmer Life Sciences) using a
RORt-GST construct produced in-house. The probe is a fluo-
rescein-labeled coactivator peptide (D22) from Invitrogen con-
taining the LXXLL motif and optimized for binding to RORt
ligand-binding domain. 10 l of compounds diluted in 20 mM
Tris, pH 7.5, 150 mM NaCl, and 0.05% CHAPS were mixed to 10
l of 2 M RORt-GST in the same buffer and incubated for 30
min at room temperature. The fluorescein D22 probe was then
added to the mixture at a final concentration of 15 nM. After 30
min of incubation at room temperature, the FP signal was mea-
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sured (excitation wavelength 480 nm; emission wavelength 535
nm).
DFT calculation
Interaction energies between His-479, Tyr-502, and Phe-506
of RORt LBD were calculated using the DFT routine imple-
mented in Jaguar (79). A hybrid functional for non-covalent
complexation energies, M06-2X (80), was applied together with
a 6 –31G** basis set to calculate DFT energies. A self-consistent
reaction field method using a Poisson Boltzmann solver (81)
was applied as continuum solvation model with a dielectric
constant of   4. Interaction energies were calculated as the
difference between the DFT energy of the residue triplet with
atomic coordinates of His-479, Tyr-502, and Phe-506 taken
from the crystal structures reported here and three DFT
energies associated with the individual residues calculated
separately. To preserve the coordinates found in the crystal
structures, only single point energies were calculated. The
interaction energies for corresponding PPAR residues were
calculated based on the same DFT method, with PPAR
coordinates taken from PDB code 1PRG.
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